Table 1.
Baseline characteristics of patients in both treatment groups
| Short-course | Long-course | p-value | |
|---|---|---|---|
| Age (yr) | 56 ± 10.3 (39–81) | 53 ± 12.9 (31–76) | 0.14 |
| Sex | 0.35 | ||
| Female | 15 | 10 | |
| Male | 18 | 17 | |
| Distance from anal verge (cm) | 9 ± 2.6 | 8 ± 3.0 | 0.80 |
| Pathology to RT (wk) (n = 53) | 6 ± 4.4 (3–23) | 6 ± 5.9 (2–34) | 0.21 |
| PTV (cm3) | 1,048 ± 269 (850–1,823) | 1,115 ± 289 (844–2,049) | 0.51 |
| ECOG performance status | 0.44 | ||
| 0 | 14 | 10 | |
| 1 | 19 | 17 | |
| Diversion colostomy | 2 (6.1) | 2 (7.4) | 0.61 |
| Elevated CEA (n = 51) | 7 (29.2) | 12 (44.4) | 0.20 |
| Histological grade (n = 48) | 0.47 | ||
| 1 | 12 (48) | 11 (47.8) | |
| 2 | 11 (44) | 7 (30.4) | |
| 3 | 2 (8) | 4 (17.4) | |
| 4 | 0 (0) | 1 (4.3) | |
| Mucinous carcinoma (n = 52) | 2 (6.5) | 5 (23.8) | 0.08 |
| Clinical stage | 0.08 | ||
| II | 8 | 2 | |
| III | 25 | 25 | |
| Clinical T status (n = 60) | 0.048 | ||
| 2 | 0 | 4 (14.8) | |
| 3 | 30 (90.9) | 19 (70.4) | |
| 4 | 3 (9.1) | 4 (14.8) | |
| Clinical N status (n = 60) | 0.109 | ||
| 0 | 8 (24.2) | 2 (7.4) | |
| 1 | 18 (54.5) | 14 (51.9) | |
| 2 | 7 (21.2) | 11 (40.7) |
Values are presented as median ± standard deviation (range) or number (%).
RT, radiotherapy; PTV, planning tumor volume; CEA, carcinoembryonic antigen.